A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients
Status:
Unknown status
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This study will treat moderate to severe rheumatoid arthritis with MRC375 (either 75 mg 3
times a day, 150 mg 3 times a day or placebo 3 times a day)in patients 18 years of age or
older that can be currently on low doses of methotrexate or can stop treatment of current RA
medications to enter the study. Safety of MRC375 will also be evaluated. There are up to 8
clinic visits over 24 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Molecular Research Center, Inc.
Collaborators:
BARC Global Central Laboratory Bilcare Global Clinical Supplies Camargo Pharmaceutical Services Clin Data Services Harrison Clinical Research